Vaccinex said that it is using its patented technology to discover and develop new monoclonal antibody therapies, and has advanced four of its lead therapeutic antibodies into preclinical drug development.
The company said that its ActivMab antibody discovery technology allows for the direct selection of high-affinity, fully human antibodies that would otherwise be difficult or impossible to identify with other systems.
Maurice Zauderer, president and CEO, said: “This European patent, and related patents already awarded in the US and elsewhere, underscores the novelty of our discovery technology, which gives Vaccinex important advantages over competitors in the area of therapeutic antibodies. Vaccinex is leveraging this patented technology in partnerships with established leaders in the antibody market as we continue to build a pipeline of promising antibody therapies.”